654 results on '"Day, R. O."'
Search Results
2. Interrogation of a longitudinal, national pharmacy claims dataset to explore factors that predict the need for add-on therapy in older and socioeconomically disadvantaged Australians with type 2 diabetes mellitus patients (T2DM)
3. The safe use of metformin in heart failure patients both with and without T2DM: a cross‐sectional and longitudinal study
4. Drug-drug interactions and their harmful effects in hospitalised patients: a systematic review and meta-analysis
5. A dosing algorithm for metformin based on the relationships between exposure and renal clearance of metformin in patients with varying degrees of kidney function
6. Trends in metformin utilisation and dose appropriateness in Australia
7. Therapeutic Considerations from Pharmacokinetics and Metabolism: Ibuprofen and Paracetamol
8. Understanding and improving the use of allopurinol in a teaching hospital
9. Does the availability of therapeutic drug monitoring, computerised dose recommendation and prescribing decision support services promote compliance with national gentamicin prescribing guidelines?
10. iPad use at the bedside: a tool for engaging patients in care processes during ward rounds?
11. Shedding light on junior doctorsʼ work practices after hours
12. A cross-sectional study of hydroxychloroquine concentrations and effects in people with systemic lupus erythematosus
13. Comparing dose prediction software used to manage gentamicin dosing
14. Formoterol, a highly β2-selective agonist, increases energy expenditure and fat utilisation in men
15. Metformin therapy in patients with chronic kidney disease
16. Initiating allopurinol therapy: do we need to know the patientʼs human leucocyte antigen status?
17. The Role and Impact of Research Agendas on the Comparative-Effectiveness Research Among Antihyperlipidemics
18. Wrong Questions, Wrong Answers? Are We Getting the Drugs We Need?
19. Current concepts of the actions of paracetamol (acetaminophen) and NSAIDs
20. Enhanced elimination of phenobarbital using charcoal haemoperfusion in a patient with severe poisoning
21. Metabolic sequelae of [beta]-blocker therapy: weighing in on the obesity epidemic?
22. Eliciting views of Australian pharmaceutical industry employees on collaboration and the concept of Quality Use of Medicines
23. CHRONIC β-BLOCKER THERAPY IS ASSOCIATED WITH LOWER PHYSICAL ACTIVITY AND OBESITY
24. Osteoarthritis antirheumatic drug trials: Effects of a standardized instructional videotape on the reliability of observer-dependent dependent outcome measures
25. Pharmacodynamic interaction of warfarin with cranberry but not with garlic in healthy subjects
26. Utilization of allopurinol in the Australian community
27. Effects of St Johnʼs wort and CYP2C9 genotype on the pharmacokinetics and pharmacodynamics of gliclazide
28. Effect of μ-opioids morphine and buprenorphine on the development of adjuvant arthritis in rats
29. Has the use of disease-modifying anti-rheumatic drugs changed as a consequence of controlled access to high-cost biological agents through the Pharmaceutical Benefits Scheme?
30. Drug Interactions of Clinical Importance: An Updated Guide
31. Giving and receiving of gifts between pharmaceutical companies and medical specialists in Australia
32. ACCESS TO BIOLOGICS FOR THE TREATMENT OF RHEUMATOID ARTHRITIS UNDER THE PHARMACEUTICAL BENEFITS SCHEME: TWO YEARS UTILISATION: AR4
33. Access to tumour necrosis factor inhibitors for rheumatoid arthritis treatment under the Australian Pharmaceutical Benefits Scheme: are we on target?
34. Inflammation '93
35. Pharmacokinetics of the enantiomers of ibuprofen in the rabbit
36. The Problems and Pitfalls of NSAID Therapy in the Elderly (Part II)
37. EFFICACY AND SAFETY OF INTRAARTICULAR HYALURONIC ACID IN OSTEOARTHRITIS
38. A COMPARISON OF THE EFFICACY OF α-KETOBUTYRIC ACID (KBA), NORDIHIDRO-GUAIARETIC ACID (NDGA), SALICYLIC ACID (SA), AND PLACEBO (P) IN THE ACCELERATED REMOVAL OF CORNS
39. DESCRIBING THE PERFORMANCE OF PHARMACY AND THERAPEUTICS COMMITTEES
40. POPULATION PHARMACOKINETICS (PK) AND PHARMACODYNAMICS (PD) OF TENOXICAM(TN) IN PATIENTS WITH RHEUMATOID ARTHRITIS (RA)
41. A COMPARATIVE ASSESSMENT OF THE SAFETY OF A NEW LIGNOCAINE SUPPOSITORY FOR THE TREATMENT OF PAINFUL HEMORRHOIDS
42. The Suction Blister as an in Vivo Model of Inflammation: Interblister Variability and Preliminary Studies of the Disposition of Methotrexate: PI-93
43. I-Methylxanthine derived from caffeine as a pharmacodynamic probe of oxypurinol effect
44. Pharmacodynamics of oxypurinol after administration of allopurinol to healthy subjects
45. Nonsteroidal Antiinflammatory Drugs — Differences and Similarities
46. A time and motion study of junior doctor work patterns on the weekend : a potential contributor to the weekend effect?
47. A time and motion study of junior doctor work patterns on the weekend: a potential contributor to the weekend effect?
48. Evaluation of Hospital-Wide Computerised Decision Support in an Intensive Care Unit: An Observational Study
49. The measurement of histamine release from suspensions of rat peritoneal cells rich in mast cells
50. Comparative efficacy trials with no placebo group cannot determine efficacy
Catalog
Books, media, physical & digital resources
Discovery Service for Jio Institute Digital Library
For full access to our library's resources, please sign in.